An interventional study of Contingent rtfMRI neurofeedback training and Non-contingent/sham rtfMRI neurofeedback training in Aging, Cognitive Change and Neurocognitive Disorders, Mild, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by University of Florida · Not applicable, Interventional, and Basic science
Among 76 studies in Neurocognitive Disorders with a site in United States — 17 open to participants now, 21 under way, 1 of them phase 3. Neurocognitive Disorders · United States.
Among the 76 studies in Neurocognitive Disorders with a site in United States, this one is the 35th largest by planned enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2024, is one of 31 with no phase, reaches primary completion later than 7 of the 20 other live ones, and was the 53rd registered.
274 studies on the registry are indexed under Neurocognitive Disorders; 90 are open to participants now.
This study's planned enrollment of 68 is below the median of 80 across 175 interventional studies indexed under Neurocognitive Disorders.
Browse Neurocognitive Disorders studies →17 of the 76 studies in Neurocognitive Disorders with a site in United States are open now.
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 59 Neurocognitive Disorders studies recruiting now, 36 (61%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 16 · Phase 3 6 · Phase 4 2
First in 2003; this study’s year is marked. 4 started in 2024.
Median enrollment 80 across the 60 interventional studies, 48 across the 15 observational. Of the 48 that completed or were terminated, 23 (48%) have results posted.
19 of 76 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,287 studies on the registry; 199 are open to participants now.
Of its 180 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 2 studies filed under Neurocognitive Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Neurocognitive Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06718140Medical University of South CarolinatFUS for Memory in mNCD and Healthy Adults | 2026-12-01 |
| NCT06036095Oregon Health and Science UniversityTotal Intravenous Versus Inhalational Anesthesia- A Geriatric Anesthesia Study | 2027-03-15 |
| NCT05457725University of FloridaModulating Neurocognitive Processes of Learning to Trust and Distrust in Aging | 2027-04-30 |
| NCT05929703University of MichiganEvaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders | 2027-05 |
| NCT06042413University of PittsburghPrediction and Prevention of Postoperative Mortality and Morbidity | 2027-10 |
Among the 76 studies in Neurocognitive Disorders with a site in United States, from their registry updates:
Much of human interaction is based on trust. Aging has been associated with deficits in trust-related decision making, likely further exacerbated in age-associated neurodegenerative disease (Alzheimer's disease/AD), possibly underlying the dramatically growing public health problem of elder fraud. Optimal trust-related decision making and avoiding exploitation require the ability to learn about the trustworthiness of social partners across multiple interactions, but the role that learning plays in determining age deficits in trust decisions is currently unknown.
Aim: Probe the malleability of the underlying neurocircuitry of trust-learning deficits in aging. This study will utilize real-time fMRI neurofeedback to train older adults in brain activity up-regulation toward enhanced trust-related learning in aging and confirm critical mechanisms of experience-dependent social decisions in aging.
Grant R01AG072658 Aim 3: Test the malleability of trust-learning neurocircuitry toward optimized trust-related decision making in aging.
This study will apply rtfMRI neurofeedback training as an intervention method, to demonstrate that older adults can be trained in volitional brain activity up-regulation, reducing their trust-learning deficits. The study will comprises several MRI sessions including pre-training, training, and post-training scans.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contingent rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about real-time brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
Behavioral: Contingent rtfMRI neurofeedback training
Non-contingent/sham rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about non-contingent/sham brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
Behavioral: Non-contingent/sham rtfMRI neurofeedback training
Contingent rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about real-time brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
Non-contingent/sham rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about non-contingent/sham brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
Neurofeedback Training Success
Increase in BOLD signal in ROI during up-regulation trials administration of computerized learning tasks, with contrasting groups and conditions
Time frame: at baseline and after training completion about 1 week later
Behavioral Benefits
Increase in trust-related learning reflected in greater accuracy (e.g., in percent) on trust learning task
Time frame: at baseline and after training completion about 1 week later
Plan to share: Undecided — De-identified data may be shared with other researchers for secondary data analysis.
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 30 months after the start.
Of 79 non-industry interventional studies with no phase under Neurocognitive Disorders, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 46. This study's planned 30 months is close to that.
Counting every sponsor, half of 82 studies reached it within 32 months; a quarter within 17 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.